PL3123381T3 - Kompozycje i sposoby związane z diagnozą raka prostaty - Google Patents

Kompozycje i sposoby związane z diagnozą raka prostaty

Info

Publication number
PL3123381T3
PL3123381T3 PL15768735.1T PL15768735T PL3123381T3 PL 3123381 T3 PL3123381 T3 PL 3123381T3 PL 15768735 T PL15768735 T PL 15768735T PL 3123381 T3 PL3123381 T3 PL 3123381T3
Authority
PL
Poland
Prior art keywords
diagnosis
compositions
prostate cancer
methods related
methods
Prior art date
Application number
PL15768735.1T
Other languages
English (en)
Inventor
David Steinmiller
Vincent Linder
Kim Pettersson
Timo Lovgren
Hans Lilja
Peter T. Scardino
Andrew J. Vickers
Original Assignee
Opko Diagnostics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics, Llc filed Critical Opko Diagnostics, Llc
Publication of PL3123381T3 publication Critical patent/PL3123381T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Evolutionary Biology (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
PL15768735.1T 2014-03-28 2015-03-27 Kompozycje i sposoby związane z diagnozą raka prostaty PL3123381T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461972099P 2014-03-28 2014-03-28
PCT/US2015/023096 WO2015148979A1 (en) 2014-03-28 2015-03-27 Compositons and methods related to diagnosis of prostate cancer

Publications (1)

Publication Number Publication Date
PL3123381T3 true PL3123381T3 (pl) 2024-02-26

Family

ID=54196462

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15768735.1T PL3123381T3 (pl) 2014-03-28 2015-03-27 Kompozycje i sposoby związane z diagnozą raka prostaty

Country Status (25)

Country Link
US (2) US11761962B2 (pl)
EP (2) EP3123381B1 (pl)
JP (3) JP6775488B2 (pl)
KR (1) KR102505543B1 (pl)
CN (2) CN114740202A (pl)
AR (1) AR099883A1 (pl)
AU (1) AU2015237270B2 (pl)
BR (1) BR112016022407A2 (pl)
CA (1) CA2944001C (pl)
CL (1) CL2016002419A1 (pl)
DE (1) DE202015009668U1 (pl)
DK (1) DK3123381T3 (pl)
EA (1) EA201691952A1 (pl)
ES (1) ES2964706T3 (pl)
FI (1) FI3123381T3 (pl)
HU (1) HUE065029T2 (pl)
IL (2) IL247981B (pl)
MX (2) MX2016012667A (pl)
MY (1) MY192513A (pl)
PE (1) PE20170298A1 (pl)
PL (1) PL3123381T3 (pl)
PT (1) PT3123381T (pl)
SG (2) SG10201808585TA (pl)
TW (1) TWI687688B (pl)
WO (1) WO2015148979A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103495439B (zh) 2007-05-04 2015-09-16 欧普科诊断有限责任公司 流体连接器和微流体系统
ES2812260T3 (es) 2009-02-02 2021-03-16 Opko Diagnostics Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
BR112014021776B1 (pt) 2012-03-05 2022-08-09 Opko Diagnostics, Llc Sistema de ensaio e método para a determinação de uma probabilidade de um evento associado com o câncer da próstata
US20170089904A1 (en) * 2014-03-28 2017-03-30 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
ES2867798T3 (es) 2015-03-27 2021-10-20 Opko Diagnostics Llc Estándares del antígeno prostático y usos de estos
EP3922265A1 (en) * 2015-10-05 2021-12-15 Fredax AB Humanized anti psa (5a10) antibodies
EP3387447A4 (en) 2015-12-11 2019-08-28 Opko Diagnostics, LLC FLUID SYSTEMS WITH INCUBATION SAMPLES AND / OR REAGENTS
WO2017116979A1 (en) 2015-12-29 2017-07-06 Opko Diagnostics, Llc Fluid collection device and related methods
JP2020507838A (ja) * 2017-01-08 2020-03-12 ザ ヘンリー エム．ジャクソン ファンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン，インコーポレーテッド 対象特有の肺炎転記を予測するための教師付き学習を使用するためのシステムおよび方法
KR102052398B1 (ko) 2018-04-18 2019-12-05 (주)유로테크 전립선암 진단용 바이오마커 및 이의 용도
WO2020205204A1 (en) 2019-04-03 2020-10-08 Opko Diagnostics, Llc Methods for the detection of prostate cancer
KR20240022906A (ko) * 2022-08-12 2024-02-20 (주)맥시온 암 진단용 다중 바이오마커 및 이의 용도
CN118629514A (zh) * 2024-08-08 2024-09-10 上海橙帆医药有限公司 序列免疫原性预测方法、装置、电子设备及存储介质

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
EP0725593B1 (en) 1993-10-28 2004-04-07 I-Stat Corporation Fluid sample collection and introduction device
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
KR19990036069A (ko) 1995-08-03 1999-05-25 이.에이치. 리링크 진단 장치
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
WO1997039351A1 (en) 1996-04-12 1997-10-23 Carter Herbert B Novel methods for the prediction and early detection of prostatic adenocarcinoma
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
SE9704934D0 (sv) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Analysförfarande med tillsättning i två eller flera positioner
FI980488A (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
FR2780791B1 (fr) 1998-07-03 2000-09-01 Bio Merieux Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
WO2000044940A2 (en) 1999-01-28 2000-08-03 Gen-Probe Incorporated Nucleic acid sequences for detecting genetic markers for cancer in a biological sample
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
EP1328342A4 (en) 2000-10-10 2006-03-15 Aviva Biosciences Corp INTEGRATED BIOCHIP SYSTEM FOR SAMPLE PREPARATION AND ANALYSIS
AU4322102A (en) 2000-11-20 2002-06-18 Eastern Virginia Med School Methods and devices for the quantitative detection of prostate specific membraneantigen and other prostatic markers
WO2003029427A2 (en) 2001-10-03 2003-04-10 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
CA2468674A1 (en) 2001-12-05 2003-06-12 University Of Washington Microfluidic device and surface decoration process for solid phase affinity binding assays
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
JPWO2003100425A1 (ja) 2002-05-28 2005-11-04 株式会社常光 免疫学的クロマトグラフ法の試験紙片の読み取り定量装置
US7605003B2 (en) 2002-08-06 2009-10-20 The Johns Hopkins University Use of biomarkers for detecting ovarian cancer
US20040115794A1 (en) 2002-12-12 2004-06-17 Affymetrix, Inc. Methods for detecting transcriptional factor binding sites
CA2513780C (en) 2003-02-07 2014-12-30 Diagnocure Inc. Method to detect prostate cancer from a urine sample
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
EP1535667A1 (en) 2003-11-28 2005-06-01 Sysmex Corporation Analyzer, assay cartridge and analyzing method
AU2003292497A1 (en) 2003-12-10 2005-06-29 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A modular biochip assembly
US7736890B2 (en) 2003-12-31 2010-06-15 President And Fellows Of Harvard College Assay device and method
PT1776181E (pt) 2004-01-26 2014-01-02 Harvard College Sistema e método para o fornecimento de fluidos
US8030057B2 (en) 2004-01-26 2011-10-04 President And Fellows Of Harvard College Fluid delivery system and method
TW200538734A (en) 2004-03-12 2005-12-01 Aureon Biosciences Corp Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
CA2564208A1 (en) * 2004-05-11 2005-11-24 Baylor College Of Medicine Method to predict prostate cancer
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
JP2008508538A (ja) 2004-08-02 2008-03-21 チルドレンズ・メディカル・センター・コーポレイション 癌についての血小板生物マーカー
CA2580494A1 (en) 2004-09-17 2006-03-30 The Johns Hopkins University Biomarkers for breast cancer
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006122310A2 (en) 2005-05-11 2006-11-16 The Trustess Of The University Of Pennsylvania System for testing
US20070065954A1 (en) 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
WO2007109881A1 (en) 2006-03-24 2007-10-04 Phenomenome Discoveries Inc. Biomarkers useful for diagnosing prostate cancer, and methods thereof
CN101506376A (zh) 2006-07-03 2009-08-12 埃克森希特医疗股份有限公司 前列腺特异性转录物及其在前列腺癌治疗和诊断中的应用
CN1973778A (zh) 2006-12-08 2007-06-06 南京大学 胃癌术后严重并发症风险度的预测方法
JP5523108B2 (ja) 2006-12-22 2014-06-18 ファディア・アクチボラグ 新規アレルゲンとしての前立腺カリクレイン
CN103495439B (zh) 2007-05-04 2015-09-16 欧普科诊断有限责任公司 流体连接器和微流体系统
JP2010528261A (ja) 2007-05-08 2010-08-19 ピコベラ・リミテッド・ライアビリティ・カンパニー 前立腺癌および肺癌の診断および治療方法
CN101329343A (zh) 2007-06-19 2008-12-24 天津迪爱盟生物技术有限公司 新一代早期诊断前列腺癌试剂盒及其制备方法和检测方法
WO2009029550A2 (en) 2007-08-24 2009-03-05 Singulex, Inc. Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CN101377500A (zh) 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 游离前列腺特异性抗原化学发光免疫分析测定试剂盒及其制备方法
WO2009052557A1 (en) 2007-10-22 2009-04-30 St Vincent's Hospital Sydney Limited Methods of prognosis
US20090226912A1 (en) 2007-12-21 2009-09-10 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
JP5028697B2 (ja) 2008-02-18 2012-09-19 富士フイルム株式会社 吸引シリンジ及び内視鏡用吸引シリンジ
JP2011521215A (ja) 2008-05-14 2011-07-21 エーテーハー チューリヒ 前立腺癌の診断及び治療のためのバイオマーカー及び薬剤標的発見法、並びにそれを用いて決定されるバイオマーカーアッセイ
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
US8386187B2 (en) 2008-10-20 2013-02-26 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
CN102308212A (zh) 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
US8591829B2 (en) 2008-12-18 2013-11-26 Opko Diagnostics, Llc Reagent storage in microfluidic systems and related articles and methods
WO2010075446A1 (en) 2008-12-23 2010-07-01 Soar Biodynamics, Ltd. Methods and systems for prostate health monitoring
US20120022793A1 (en) 2009-01-19 2012-01-26 Miraculins, Inc. Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population
ES2812260T3 (es) 2009-02-02 2021-03-16 Opko Diagnostics Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
JP2010243406A (ja) 2009-04-08 2010-10-28 F Hoffmann La Roche Ag Ａｆｐおよびｐｉｖｋａ−ｉｉの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法
CA2760333A1 (en) 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
WO2010139711A1 (en) 2009-06-04 2010-12-09 Metanomics Health Gmbh Means and methods for diagnosing prostate carcinomas
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027310A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
KR101141190B1 (ko) * 2009-10-19 2012-06-13 중앙대학교 산학협력단 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단
AU2011225716A1 (en) * 2010-03-11 2012-09-27 Pfizer Inc. Antibodies with pH dependent antigen binding
MX2012012066A (es) 2010-04-16 2012-12-17 Opko Diagnostics Llc Control de retroalimentacion en sistemas microfluidicos.
WO2012029080A1 (en) 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
WO2012129408A2 (en) 2011-03-22 2012-09-27 The Johns Hopkins University Biomarkers for aggressive prostate cancer
US20140227720A1 (en) 2011-06-09 2014-08-14 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
WO2013012028A1 (ja) 2011-07-21 2013-01-24 和光純薬工業株式会社 血漿中アミノ酸分析用標準液
EP2771037B1 (en) 2011-10-28 2016-08-03 Fredax AB Therapeutic agents and uses thereof
WO2013106778A2 (en) 2012-01-13 2013-07-18 Iris International, Inc. Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
BR112014021776B1 (pt) * 2012-03-05 2022-08-09 Opko Diagnostics, Llc Sistema de ensaio e método para a determinação de uma probabilidade de um evento associado com o câncer da próstata
EP2850432A2 (en) * 2012-05-16 2015-03-25 Phadia AB Method for indicating the presence or non-presence of prostate cancer
EP2867375B1 (en) 2012-06-27 2019-02-27 Berg LLC Use of markers in the diagnosis and treatment of prostate cancer
CN102818892B (zh) 2012-08-16 2015-02-18 北京恩济和生物科技有限公司 一种前列腺特异性抗原检测试剂盒及其制备方法
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
CA2891394C (en) 2012-11-20 2023-03-14 Phadia Ab Prognostic method for individuals with prostate cancer
JP2016503301A (ja) 2012-11-20 2016-02-04 ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ 侵攻性前立腺癌の存在または不存在を判定する方法
KR102442738B1 (ko) 2013-11-19 2022-09-15 프레닥스 에이비 인간화된 안티 칼리크레인-2 항체
DK3117216T3 (da) 2014-03-11 2023-04-03 Phadia Ab Fremgangsmåde til detektering af en solid tumor-cancer
US20170089904A1 (en) 2014-03-28 2017-03-30 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
WO2016145331A1 (en) 2015-03-12 2016-09-15 Thermo Finnigan Llc Methods for data-dependent mass spectrometry of mixed biomolecular analytes
ES2867798T3 (es) 2015-03-27 2021-10-20 Opko Diagnostics Llc Estándares del antígeno prostático y usos de estos
EA039028B1 (ru) 2015-04-29 2021-11-24 Опкоу Дайагностикс, Ллк Способ, компьютер и система для определения вероятности события, ассоциированного с раком предстательной железы
US20190072555A1 (en) 2017-08-14 2019-03-07 Opko Diagnostics, Llc Multiplex assays for evaluating prostate cancer status
EP3794354A4 (en) 2018-05-16 2022-01-12 Opko Diagnostics, LLC METHODS OF DETECTING PROSTATE CANCER ASSOCIATED WITH NEGATIVE RESULTS

Also Published As

Publication number Publication date
DE202015009668U1 (de) 2019-01-21
CA2944001A1 (en) 2015-10-01
IL280039A (en) 2021-03-01
US20230393137A1 (en) 2023-12-07
JP7506131B2 (ja) 2024-06-25
AU2015237270B2 (en) 2021-09-09
CN106663149A (zh) 2017-05-10
US11761962B2 (en) 2023-09-19
MY192513A (en) 2022-08-24
HUE065029T2 (hu) 2024-04-28
JP6775488B2 (ja) 2020-10-28
ES2964706T3 (es) 2024-04-09
EP3123381A4 (en) 2018-02-21
TWI687688B (zh) 2020-03-11
JP2021009157A (ja) 2021-01-28
DK3123381T3 (da) 2023-11-27
KR20170008729A (ko) 2017-01-24
MX2016012667A (es) 2017-01-09
IL280039B (en) 2021-12-01
JP2017515127A (ja) 2017-06-08
PE20170298A1 (es) 2017-04-18
BR112016022407A2 (pt) 2017-12-12
CN114740202A (zh) 2022-07-12
WO2015148979A8 (en) 2016-01-07
IL247981A0 (en) 2016-11-30
US20160025732A1 (en) 2016-01-28
PT3123381T (pt) 2023-12-22
SG11201608035UA (en) 2016-10-28
AU2015237270A1 (en) 2016-10-20
EP3299977A1 (en) 2018-03-28
TW201621320A (zh) 2016-06-16
SG10201808585TA (en) 2018-11-29
CL2016002419A1 (es) 2017-03-31
CA2944001C (en) 2023-08-15
FI3123381T3 (fi) 2023-11-27
IL247981B (en) 2021-02-28
EP3123381A1 (en) 2017-02-01
EA201691952A1 (ru) 2017-05-31
JP7256781B2 (ja) 2023-04-12
KR102505543B1 (ko) 2023-03-02
MX2022002365A (es) 2022-04-06
WO2015148979A1 (en) 2015-10-01
EP3123381B1 (en) 2023-10-11
JP2023017841A (ja) 2023-02-07
AR099883A1 (es) 2016-08-24

Similar Documents

Publication Publication Date Title
IL280039A (en) Preparations and methods related to the diagnosis of prostate cancer
IL273090B (en) Methods and preparations for the treatment of cancer
EP3186393A4 (en) Methods and compositions related to prostate cancer therapeutics
HK1247931A1 (zh) 用於診斷和治療癌症的組合物和方法
HK1211963A1 (en) Compositions and methods for diagnosis and treatment of hepatic cancers
ZA201701909B (en) Trichoderma compositions and methods of use
SG11201607795UA (en) Inos-inhibitory compositions and their use as breast cancer therapeutics
SG11201701076TA (en) Diagnosis of cancer
EP4043567C0 (en) METHOD AND COMPOSITIONS FOR TREATMENT OF CANCER
EP2958591A4 (en) METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF CANCER
IL259781A (en) Uses of pyrimido-pyridazinones to treat cancer
HK1243404A1 (zh) 色酰胺組合物和使用方法
HK1213740A1 (zh) 製備抗癌症組合物的方法
ZA201506392B (en) Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
GB201407837D0 (en) Methods of cancer therapy
TH1501005132A (th) องค์ประกอบ และวิธีการสำหรับการวินิจฉัย และการรักษามะเร็งตับ
GB201410695D0 (en) Uses of oligouronates in cancer treatment
ZA201403006B (en) Composition for use in treatment of cancer
GB201405075D0 (en) Treatment of cancer